The effect of a mineralocorticoid receptor antagonist eplerenone on morning home BP in drug-resistant hypertension

The effect of a mineralocorticoid receptor antagonist eplerenone on morning home BP in drug-resistant hypertension - Eplerenone study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014186

Enrollment

100

Registered

2014-06-20

Start date

2010-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-resistant morning hypertension

Interventions

CCB, RAS inhibitors, and diuretics CCB, RAS inhibitors, diuretics and eplerenone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with drug-resistant hypertension who were treated by at least 3 antihypertensive drugs (CCB, RAS inhibitors, and diuretics) more than 3 months. (2)Despite above treatment plus non-pharmacological treatments (Diet and exercise), home morning was > or = 135/85mmHg (either).

Exclusion criteria

Exclusion criteria: 1.Diabetes with albuminuria or proteinuria 2.Allergy, or allergic reaction to study drugs 3. Patients with Hyperkalemia or serum potassium level>5.0mEq/ 4.Renal dysfunction (Ccr<50ml/min) 5.Sevre Hepatic damage 6.Taking potassium, or spironolactone 7.Taking Itraconazole, Ritonavir, and Nelfinavir 8. age<20yrs, or dementia 9. Not appropriate for the study.

Design outcomes

Primary

Measure	Time frame
Antihypertensive effects of home blood pressure between group I and II in the interventional period 1, and group III and IV in the interventional period 2 will be compared.	—

Countries

Japan

Contacts

Public ContactSatoshi Hoshide

Jichi Medical University School of Medicine Division of Cardiovascular Medicine, Department of Medicine

hoshide@jichi.ac.jp0285-58-7344

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026